Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of New CC-220 Formulation in Healthy Adults
NCT03135509Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iberdomide in systemic lupus erythematosus (SLE) and multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at 1 month and Area Under the Curve from Time Zero to Last Quantifiable Concentration at 1 month. Started May 2017; status: completed.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03135509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135509.